诺华地拉罗司进医保了吗？

Thalassemia (thalassemia for short) is a group of hereditary hemolytic anemias. As the most common single-gene genetic disease in humans, thalassemia is inherited with incomplete autosomal dominant inheritance. The treatment of thalassemia mainly relies on regular blood transfusion and iron removal therapy. Novartis (Enrig) ​​is used in patients with iron accumulation due to long-term blood transfusions.

Novartis is a multinational group in the global pharmaceutical and healthcare industry, headquartered in Basel, Switzerland, with operations in more than 140 countries and regions around the world. Novartis was founded in 1996 from the merger of two Basel-based chemical and pharmaceutical companies, Ciba-Geigy and Sandoz. Novartis focuses on the growth areas of pharmaceuticals and health care, and has a diversified business portfolio of innovative drugs, preventive vaccines and diagnostic reagents, as well as consumer health products. Novartis is the only company with a leading position in the above four fields.

In 2010, Novartis deferasirox (Enrige) was approved for marketing in China for the treatment of chronic iron overload caused by frequent blood transfusions (monthly dosage of concentrated red blood cells ≥7 mL/kg) in patients with β-thalassemia over 6 years old. For children under 6 years old and iron overload caused by other transfusion-dependent diseases, the safety and effectiveness data of deferasirox (Enrige) in Chinese patients are limited, and it is recommended to use it with caution based on the specific conditions of the patients.

Is Novartis deferasirox covered by medical insurance?

Novartis has entered the medical insurance, and deferasirox is included in the National Medical Insurance (2019 Edition) Category B, Miscellaneous > Other Therapeutic Drugs > Other Therapeutic Drugs > Iron Chelating Agents (XV>

Recommended related hot articles: /newsDetail/88619.html